结肠癌腹膜转移癌的当前治疗选择。
Current treatment options for colon cancer peritoneal carcinomatosis.
作者信息
Aoyagi Tomoyoshi, Terracina Krista P, Raza Ali, Takabe Kazuaki
机构信息
Tomoyoshi Aoyagi, Krista P Terracina, Ali Raza, Kazuaki Takabe, Division of Surgical Oncology, Department of Surgery, Virginia Commonwealth University School of Medicine, Richmond, VA 23298-0011, United States.
出版信息
World J Gastroenterol. 2014 Sep 21;20(35):12493-500. doi: 10.3748/wjg.v20.i35.12493.
Abstract
Peritoneal carcinomatosis (PC), the dissemination of cancer cells throughout the lining of the abdominal cavity, is the second most common presentation of colon cancer distant metastasis. Despite remarkable advances in cytotoxic chemotherapy and targeted therapy for colon cancer over the last 15 years, it has been repeatedly shown that these therapies remain ineffective for colon cancer PC. Recently, there has been a rapid accumulation of reports that cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy (CRS-HIPEC) prolongs the life of colon cancer PC patients. Here, we will review the clinical presentation, the mechanisms of disease progression, and current treatment options for colon cancer PC, with a focus on the benefits and limitations of CRS-HIPEC.
摘要
腹膜癌病（PC）是指癌细胞在整个腹腔内衬层播散，是结肠癌远处转移的第二常见表现形式。尽管在过去15年中，细胞毒性化疗和结肠癌靶向治疗取得了显著进展，但反复表明这些疗法对结肠癌PC仍然无效。最近，有大量报道迅速积累，表明减瘤手术联合腹腔内热灌注化疗（CRS-HIPEC）可延长结肠癌PC患者的生命。在此，我们将综述结肠癌PC的临床表现、疾病进展机制和当前治疗选择，重点关注CRS-HIPEC的益处和局限性。
相似文献
1
Current treatment options for colon cancer peritoneal carcinomatosis.结肠癌腹膜转移癌的当前治疗选择。
World J Gastroenterol. 2014 Sep 21;20(35):12493-500. doi: 10.3748/wjg.v20.i35.12493.
2
Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy with lobaplatin and docetaxel improves survival for patients with peritoneal carcinomatosis from abdominal and pelvic malignancies.细胞减灭术联合洛铂和多西他赛腹腔热灌注化疗可改善腹盆腔恶性肿瘤腹膜转移患者的生存情况。
World J Surg Oncol. 2016 Sep 15;14(1):246. doi: 10.1186/s12957-016-1004-4.
3
Prognostic factor analysis of circulating tumor cells in peripheral blood of patients with peritoneal carcinomatosis of colon cancer origin treated with cytoreductive surgery plus an intraoperative hyperthermic intraperitoneal chemotherapy procedure (CRS + HIPEC).接受细胞减灭术加术中腹腔内热化疗（CRS + HIPEC）治疗的结肠癌源性腹膜癌患者外周血循环肿瘤细胞的预后因素分析
Surgery. 2016 Mar;159(3):728-35. doi: 10.1016/j.surg.2015.09.013. Epub 2015 Oct 28.
4
Repeated cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in peritoneal carcinomatosis from appendiceal cancer: analysis of survival outcomes.阑尾癌腹膜转移行多次细胞减灭术和腹腔热灌注化疗：生存结局分析。
Eur J Surg Oncol. 2013 Nov;39(11):1207-13. doi: 10.1016/j.ejso.2013.08.017. Epub 2013 Sep 2.
5
Systemic Chemotherapy using FLOT - Regimen Combined with Cytoreductive Surgery plus HIPEC for Treatment of Peritoneal Metastasized Gastric Cancer.采用FLOT方案的全身化疗联合减瘤手术加腹腔热灌注化疗治疗腹膜转移胃癌
Hepatogastroenterology. 2014 May;61(131):703-6.
6
Role of CRS and HIPEC in appendiceal and colorectal malignancies: Indian experience.细胞减灭术和热灌注化疗在阑尾及结直肠癌中的作用：印度经验
Indian J Gastroenterol. 2017 Mar;36(2):126-130. doi: 10.1007/s12664-017-0747-3. Epub 2017 Apr 10.
7
Routine second-look after surgical treatment of colonic peritoneal carcinomatosis.结肠腹膜癌病手术治疗后的常规二次探查。
J Visc Surg. 2015 Jun;152(3):149-54. doi: 10.1016/j.jviscsurg.2015.01.002. Epub 2015 Jan 31.
8
Peritoneal carcinomatosis arising from rectal or colonic adenocarcinoma treated with cytoreductive surgery (CRS) hyperthermic intraperitoneal chemotherapy (HIPEC): two different diseases.源于直肠或结肠腺癌的腹膜癌病经细胞减灭术（CRS）联合腹腔热灌注化疗（HIPEC）治疗：两种不同的疾病。
Clin Transl Oncol. 2018 Oct;20(10):1268-1273. doi: 10.1007/s12094-018-1857-9. Epub 2018 Apr 17.
9
10
Peritonectomy procedures and HIPEC in the treatment of peritoneal carcinomatosis from ovarian cancer: Long-term outcomes and perspectives from a high-volume center.腹膜切除术及腹腔热灌注化疗治疗卵巢癌腹膜转移癌：来自高容量中心的长期疗效及展望
Eur J Surg Oncol. 2016 Feb;42(2):224-33. doi: 10.1016/j.ejso.2015.11.006. Epub 2015 Nov 25.
引用本文的文献
1
Efficacy and safety of regorafenib in the treatment of metastatic colorectal cancer: a retrospective cohort study.瑞戈非尼治疗转移性结直肠癌的疗效与安全性：一项回顾性队列研究
J Gastrointest Oncol. 2024 Jun 30;15(3):987-1001. doi: 10.21037/jgo-24-180. Epub 2024 Jun 18.
2
TP53TG1/STAT axis is involved in the development of colon cancer through affecting PD-L1 expression and immune escape mechanism of tumor cells.TP53TG1/STAT轴通过影响肿瘤细胞的PD-L1表达和免疫逃逸机制参与结肠癌的发生发展。
Am J Cancer Res. 2023 Nov 15;13(11):5218-5235. eCollection 2023.
3
Protease-activated receptor 2 attenuates doxorubicin-induced apoptosis in colon cancer cells.蛋白酶激活受体2减轻阿霉素诱导的结肠癌细胞凋亡。
J Cell Commun Signal. 2023 Dec;17(4):1293-1307. doi: 10.1007/s12079-023-00791-6. Epub 2023 Nov 22.
4
Comparison of genetic variation between primary colorectal cancer and metastatic peritoneal cancer.原发结直肠癌与转移性腹膜癌的遗传变异比较。
Genes Genomics. 2023 Aug;45(8):989-1001. doi: 10.1007/s13258-023-01408-3. Epub 2023 Jun 5.
5
Triple-Therapy of Peritoneal Metastasis-Partial-Dehydration under Hyperthermic Condition Combined with Chemotherapy: The First Preliminary In-Vitro Results.腹膜转移三联疗法——高温条件下部分脱水联合化疗：首个初步体外实验结果
Pharmaceuticals (Basel). 2023 May 18;16(5):763. doi: 10.3390/ph16050763.
6
NXNL2 Promotes Colon Cancer Proliferation and Metastasis by Regulating AKT Pathway.NXNL2 通过调控 AKT 通路促进结肠癌的增殖和转移。
Appl Biochem Biotechnol. 2023 Dec;195(12):7685-7696. doi: 10.1007/s12010-023-04513-x. Epub 2023 Apr 21.
7
Evaluating the concept of gas‑based intraperitoneal hyperthermia beyond 43˚C in the treatment of peritoneal metastasis: A pilot study.评估超过43˚C的气体腹腔内热疗概念在腹膜转移治疗中的应用：一项前瞻性研究。
Exp Ther Med. 2022 Nov 8;24(6):752. doi: 10.3892/etm.2022.11687. eCollection 2022 Dec.
8
Hyperthermic Intraperitoneal Chemotherapy and Recirculation with CO: A Safe Technique.腹腔内热化疗与二氧化碳再循环：一种安全技术。
J Clin Med. 2022 Oct 19;11(20):6152. doi: 10.3390/jcm11206152.
9
Is Pressurized Intraperitoneal Aerosolized Chemotherapy (PIPAC) Effective in Ovarian Cancer With Peritoneal Metastasis?加压腹腔雾化化疗（PIPAC）对伴有腹膜转移的卵巢癌有效吗？
Cureus. 2022 Aug 9;14(8):e27837. doi: 10.7759/cureus.27837. eCollection 2022 Aug.
10
thermodynamic exploration of gas-based intraperitoneal hyperthermia.基于气体的腹腔内热疗的热力学探索
Front Oncol. 2022 Aug 29;12:925724. doi: 10.3389/fonc.2022.925724. eCollection 2022.
本文引用的文献
1
Cytoreduction and heated intraperitoneal chemotherapy for colorectal cancer: are we excluding patients who may benefit?结直肠癌的细胞减灭术和腹腔内热化疗：我们是否排除了可能受益的患者？
J Surg Oncol. 2014 Feb;109(2):104-9. doi: 10.1002/jso.23446.
2
Individualized prediction of risk of metachronous peritoneal carcinomatosis from colorectal cancer.结直肠癌异时性腹膜癌转移风险的个体化预测
Colorectal Dis. 2014 May;16(5):359-67. doi: 10.1111/codi.12552.
3
Surgery for colorectal liver metastases: The evolution of determining prognosis.结直肠癌肝转移的手术治疗：预后判定的演变
World J Gastrointest Oncol. 2013 Dec 15;5(12):207-21. doi: 10.4251/wjgo.v5.i12.207.
4
Peritoneal carcinomatosis.腹膜癌病。
World J Gastroenterol. 2013 Nov 7;19(41):6979-94. doi: 10.3748/wjg.v19.i41.6979.
5
Metachronous peritoneal carcinomatosis after curative treatment of colorectal cancer.结直肠癌根治性治疗后发生的异时性腹膜癌转移
Eur J Surg Oncol. 2014 Aug;40(8):963-9. doi: 10.1016/j.ejso.2013.10.001. Epub 2013 Oct 16.
6
Survival after liver resection in metastatic colorectal cancer: review and meta-analysis of prognostic factors.转移性结直肠癌肝切除术后的生存：预后因素的综述和荟萃分析。
Clin Epidemiol. 2012;4:283-301. doi: 10.2147/CLEP.S34285. Epub 2012 Nov 7.
7
HIPEC + EPIC versus HIPEC-alone: differences in major complications following cytoreduction surgery for peritoneal malignancy.HIPEC+EPIC 与 HIPEC 单药治疗：细胞减灭术治疗腹膜恶性肿瘤后主要并发症的差异。
J Surg Oncol. 2013 May;107(6):591-6. doi: 10.1002/jso.23276. Epub 2012 Nov 5.
8
Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: where are we?细胞减灭术和腹腔内热灌注化疗：我们在哪里？
World J Gastroenterol. 2012 Oct 14;18(38):5317-20. doi: 10.3748/wjg.v18.i38.5317.
9
Incidence, prevalence and risk factors for peritoneal carcinomatosis from colorectal cancer.结直肠癌腹膜转移的发生率、患病率和危险因素。
Br J Surg. 2012 May;99(5):699-705. doi: 10.1002/bjs.8679. Epub 2012 Jan 27.
10
Multimodal treatment approaches for peritoneal carcinosis in colorectal cancer.结直肠癌腹膜转移的多模态治疗方法。
Dtsch Arztebl Int. 2011 Nov;108(47):802-8. doi: 10.3238/arztebl.2011.0802. Epub 2011 Nov 25.
Zotero 插件